Hoosiers Work for Health

Making prescription drugs more accessible and affordable sounds great in theory, but everyone seems to have different ideas on how to make that happen. Adina Lasser, director of public policy and government relations for Alliance for Aging Research, breaks down the complex landscape of federal drug pricing policy with Medical Economics and what patients and physicians need to know.

Access, affordability, ambiguity: Who really benefits from federal prescription drug price policies? | Medical Economics A policy expert explains what physicians need to know when patients ask about the changing prices of their medicines.

European experts are not speaking hypothetically. As director of the Austrian Economics Center and a member of Austria’s National Council, Barbara Kolm has direct experience with the European drug pricing systems some want the U.S. to adopt. Her warning about the risks to innovation and future cures should not be taken lightly.

Don’t follow us into ‘most-favored-nation’ drug pricing Today, medical leaps that once took decades are now happening in months.